News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Ondine Biomedical Inc Announces Corporate and Trading Update
Ondine Biomedical (LON:OBI) reports significant revenue growth and commercial momentum in 2023 with doubled revenues and increased number of hospital deployments, including strategic inroads in the UK, Spain, and Australia. The company also announces distribution partnerships and plans for US Phase 3 Clinical Trial -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Ondine Biomedical Inc. Announces 32% Fewer SSIs After Steriwave Replaced Mupirocin
Study at Mazankowski Alberta Heart Institute shows 32% reduction in cardiac infections with Steriwave replacing antibiotic standard. Significant cost savings and high compliance. Expert commentary available